Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study.
Tabrizi
S J
SJ
Department of Neurodegenerative Disease, Institute of Neurology, Queen Square, London, UK.
Blamire
A M
AM
Manners
D N
DN
Rajagopalan
B
B
Styles
P
P
Schapira
A H V
AH
Warner
T T
TT
D000255:Adenosine Triphosphate / Q000378:metabolism; D001224:Aspartic Acid / Q000031:analogs & derivatives* / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D002794:Choline / Q000378:metabolism; D003401:Creatine / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D003967:Diarrhea / Q000139:chemically induced; D019587:Dietary Supplements; D004305:Dose-Response Relationship, Drug; D006801:Humans; D006816:Huntington Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D009682:Magnetic Resonance Spectroscopy; D018482:Muscle, Skeletal / Q000378:metabolism; D009325:Nausea / Q000139:chemically induced; D009483:Neuropsychological Tests; D010725:Phosphocreatine / Q000378:metabolism; D010865:Pilot Projects; D012016:Reference Values; D012449:Safety; D016896:Treatment Outcome
D010725:Phosphocreatine; D001224:Aspartic Acid; D000255:Adenosine Triphosphate; C000179:N-acetylaspartate; D003401:Creatine; D002794:Choline